Taken together, our findings suggest that further characterisation of GALNT7 mediated O-glycosylation, alongside a systematic study of O-glycosylation in prostate tumours, will reveal novel biomarkers and potential therapeutic targets to provide clinically actionable information that could impact men with prostate cancer. The gene discussed is GALNT7; the disease is prostate neoplasm.